Ocular Therapeutix has commercially launched Dextenza in the United States for the treatment of ocular inflammation and pain after ophthalmic surgery, according to a press release.
The first FDA-approved intracanalicular insert, Dextenza (dexamethasone ophthalmic insert 0.4 mg) was approved in November 2018 for ocular pain and in June for ocular inflammation.
The launch is supported by the activation of a CMS C-code, C9048, which allows reimbursement for Dextenza until CMS approves a J-code.
“With reimbursement solidified through a unique C-code, the addition of inflammation to our label
Uncategorized